Human papillomavirus (HPV) is the leading cause of several cancers, including cervical cancer – yet largely preventable through early screening. However, millions of people are not getting screened, held back by practical, financial, or psychological barriers: waiting times, consultation costs, lack of information, or discomfort.
Papilio.bio addresses these health inequalities with an HPV self-test that is rapid and for home use, accompanied by an app that guides the user through result interpretation, medical follow-up, and access to educational content. A simple, accessible, and confidential solution – to finally make prevention everyone's business.
The next step
Papilio.bio is entering a pivotal phase: to close a funding round to finance the deployment of its solution and accelerate its market entry. A decisive milestone to transform a promising medical innovation into a widely accessible public health tool.
Why 21st by CentraleSupélec?
Fundraising in MedTech and building a solid market strategy are two demanding disciplines, especially in a sector as regulated as healthcare. 21st by CentraleSupélec supports Papilio.bio on both these fronts: preparing the fundraising round meticulously, and refine the market strategy to reach the right people at the right time.
Focus on the co-founders
Chiara Cespi Polisiani, Serena Petracchini
#Femtech #Prevention #HPVScreening #MedicalInnovation #HealthForAll
.avif)
